Sentences with phrase «division of oncology»

Shiven B. Patel, M.D., M.B.A., is a Clinical Instructor in the Division of Oncology, Department of Medicine, at the University of Utah, School of Medicine, and an Investigator at the Huntsman Cancer Institute.

John F. DiPersio, MD, PhD Virginia E. and Samuel J. Golman Professor Chief, Division of Oncology Deputy Director, Alvin J. Siteman Cancer Center Washington University School of Medicine St Louis, MO

The more it's expressed only on cancer cells, the more targeted the therapy becomes,» says Colin Weekes, MD, PhD, CU Cancer Center investigator and assistant professor in the Division of Oncology at the CU School of Medicine.

Not exact matches

Prior to this role, Derek was a Senior Associate on the Landscape Team within the TechAtlas division of RA Capital, where he mapped competitive landscapes in the solid tumor oncology space and performed in - depth analyses of pharma pipelines.

Julia has also mapped competitive landscapes with a focus on immuno - oncology and melanoma as a member of the Oncology Team within the TechAtlas division of RA oncology and melanoma as a member of the Oncology Team within the TechAtlas division of RA Oncology Team within the TechAtlas division of RA Capital.

«Although FDA approval is critically important for introducing a new screening test or algorithm, providers ultimately rely on guidance or guidelines to help them make the best decisions for their patients and want to understand advantages, disadvantages and unknowns associated with a new screening approach,» said Huh, who is a senior scientist for the UAB Comprehensive Cancer Center, Director of the UAB Division of Gynecologic Oncology, and is also a board member for both the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology.

The results were indeed a surprise — at first, says Kalpna Gupta, a co-author of the 2002 paper and an assistant professor in the Hematology, Oncology and Transplantation Division in the Department of Medicine at the University of Minnesota.

The protein puts the immune system's brakes on, keeping its T cells from recognizing and attacking cancer cells, said Dr. Antoni Ribas, the study's principal investigator and a professor of medicine in the division of hematology - oncology at the David Geffen School of Medicine at UCLA.

«Understanding how drug resistance develops can help in the design of new agents or strategies to overcome resistance,» says principal investigator Sameek Roychowdhury, MD, PhD, assistant professor of medicine and of pharmacology in the Division of Medical Oncology at the OSUCCC — James.

Monica Bertagnolli, chief of the Division of Surgical Oncology at Brigham and Women's Hospital and chair of the Alliance for Clinical Trials in Oncology, a nationwide effort to test new therapies, says she was thrilled that the president used the word «cure» in his speech at all.

The research team, led by senior author Timothy P. Cripe, MD, PhD, chief of the Division of Hematology / Oncology / BMT at Nationwide Children's Hospital, found that virotherapy doesn't always require a strong virus infection of cancer cells to cause tumors to shrink or die.

Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine and Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, 550 North Broadway, Baltimore, MD 21205, USA.

«Massachusetts has a very vibrant community with the proximity of Harvard and MIT,» says Leonard Zon, with the stem cell program and division of hematology / oncology, Children's Hospital.

«This study opens the door for combination therapy with BRAF inhibitors and autophagy inhibitors, which haven't been explored deeply as a therapeutic option for patients whose tumors are resistant,» said Ravi K. Amaravadi, MD, assistant professor of Medicine in the division of Hematology / Oncology at the Perelman School of Medicine and co-leader of the Cancer Therapeutics Program at Penn Medicine's Abramson Cancer Center.

This is the first study to show the role that type I interferon plays in driving the body's immune destruction during HIV infection, said Scott Kitchen, associate professor of medicine in the division of hematology / oncology at the David Geffen School of Medicine at UCLA and senior author of the study published in the peer - reviewed Journal of Clinical Investigation.

Stem Cell Program, Division of Hematology and Oncology, Pediatric Hematology Program, Boston Children's Hospital and Dana - Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Principal investigator Leena Gandhi, MD, PhD, director of the thoracic medical oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago.

The trial was run by Professor Bradley J. Monk MD who directs the Division of Gynecologic Oncology at the University of Arizona Cancer Center at St. Joseph's in Phoenix and sponsored by Amgen.

Researchers include first author David L. Bajor, MD, instructor of Medicine in the division of Hematology / Oncology, and senior author Robert H. Vonderheide, MD, DPhil, the Hanna Wise Professor in Cancer Research.

Lymphoma Genomic Translational Research Laboratory, Division of Medical Oncology, National Cancer Centre Singapore, Singapore 169610, Singapore.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

In 1996, I relinquished an endowed chair of oncology at UNC Chapel Hill to become the scientific director of the Division of Clinical Sciences at the National Cancer Institute (NCI) near Washington, D.C..

Stewart Massad is chief of the gynecologic oncology division at the Southern Illinois University School of Medicine in Springfield.

«The link between metabolism and cancer has been proposed or inferred to exist for a long time, but what is more scarce is evidence for a direct connection — genetic mutations in metabolic enzymes,» said senior author Ricardo C.T. Aguiar, M.D., Ph.D., associate professor of hematology - oncology in the School of Medicine and a faculty scientist with the Cancer Therapy & Research Center (CTRC) at the UT Health Science Center and the South Texas Veterans Health Care System, Audie L. Murphy Division.

«This is the first national study to identify specific regions of the United States where residents may be at an increased risk for poor clinical outcomes — including misdiagnoses and late detection — as a result of limited access to specialized gynecologic cancer care,» says David Shalowitz, MD, a fellow in the division of Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author on the study.

«Identification of these variations has helped the family to better understand why their children developed cancer and to plan for the future,» said co-author Kim Nichols, M.D., a member of the St. Jude Oncology department and director of the St. Jude Cancer Predisposition Division.

«Now that we know exactly how changes in EMSY spur cancer cell growth, we can start to design therapies to specifically target that activity and hopefully stop it,» says senior author Douglas Levine, MD, director of the Division of Gynecologic Oncology at NYU Langone and its Perlmutter Cancer Center.

To investigate, a team led by Gerburg Wulf, MD, PhD, a physician scientist in the Hematology / Oncology Division at Beth Israel Deaconess Medical Center (BIDMC) and an Associate Professor of Medicine at Harvard Medical School, cultured breast cells called primary mammary epithelial cells (MECs) in the presence of EBV.

«Until now, physicians have taken a «wait and see» approach to antiviral therapies following transplantation,» says Toor, a hematologist - oncologist in the Bone Marrow Transplant Program and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine.

Either drink delivers a sugar shot that increases insulin and insulinlike growth factor, «both of [which] promote inflammation and both lead to cancer cell division,» says Abrams, who is also professor of clinical medicine at U.C.S.F., and chief of hematotology / oncology at San Francisco General Hospital.

That's given us the parts list,» said study co-senior author William Hahn, an institute member in the Broad Cancer Program, chief of the Division of Molecular and Cellular Oncology at Dana - Farber, and a leader in the Cancer Dependency Map initiative, a joint effort spanning the Broad Institute and Dana - Farber.

Published by Noha Sharafeldin, M.D., M.Sc., Ph.D., instructor in UAB's Institute for Cancer Outcomes and Survivorship and Division of Hematology and Oncology, this study helps add a missing piece to a long - unsolved puzzle about post-transplant effects on recipients, specifically that vulnerable subpopulations of similar transplants can benefit from targeted interventions in the years after they receive their lifesaving treatment.

Tweardy is division head of internal medicine and a professor of infectious diseases and molecular and cellular oncology at MD Anderson.

Hayley Knollman, MD, has joined the Division of Hematology / Oncology at the Abramson Cancer Center.

Division of Gastroenterology and Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111

Division of Hematology / Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana - Farber Cancer Institute, Howard Hughes Medical Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115

Since 2000 Head of Lymphocyte Activation Unit Division of Immunology, Transplantation and Infectious Diseases Program in Immunology, Bio-Immuno-gene therapy of Cancer, IRCCS Ospedale San Raffaele, Milan, Italy 1998 - 1999 Research Associate Department of Molecular Biology and Functional Genomic, IRCCS Ospedale San Raffaele, Milan, Italy 1993 - 1998 Postdoctoral Associate Department of Microbiology University of Minnesota, Medical School Minneapolis, MN, USA 1991 - 1992 Department of Pharmacology, New York University, New York, USA 1989 - 1991 Department of Biomedical Science and Oncology, Turin, Italy 1988 - 1989 Research Fellow Department of Biomedical Science and Oncology, Turin, Italy 1989 - 1992 Ph.D. student in Molecular Oncology 1986 - 1988 Undergraduate student Department of Biomedical Science and Oncology, Turin, Italy

I completed my fellowship in 1983 and joined the faculty of Pediatrics in the Division of Pediatric Hematology - Oncology at Duke at that time.

«Based on a better understanding of its origins, our study suggests new strategies for the prevention and early detection of ovarian cancer,» senior study author Douglas A. Levine, MD, director of the Division of Gynecologic Oncology at Perlmutter Cancer Center and professor of obstetrics and gynecology at NYU School of Medicine, tells Medscape.

Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226;

Based on our findings, the occurrence of cancer is much higher in adults over 75 years of age compared with the proportion of patients in this age group who enroll in clinical trials,» said lead study author Bindu Kanapuru, MD, medical officer in the Division of Hematology Products, Office of Hematology and Oncology Products in the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, who presented the results at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9 — 12 in Atlanta.

Carrie Kitko, M.D., joined the Vanderbilt Pediatric Hematology / Oncology division as the Medical Director of the Pediatric Stem Cell Transplant Program in June 2015.

Dr. Rajen Mody joined the Division of Pediatric Hematology / Oncology following completion of his fellowship training in pediatric hematology / oncology at the University of MOncology following completion of his fellowship training in pediatric hematology / oncology at the University of Moncology at the University of Michigan.

In this video, Yousef N. Zakharia, MD, of the Holden Comprehensive Cancer Center and division of hematology and medical oncology at the University of Iowa, discusses phase II results of a single - arm trial that tested checkpoint inhibition plus indoximod, an IDO - pathway inhibitor, in patients with advanced melanoma.

Howard Safran, MD, Interim Division Director, Division of Hematology / Oncology and professor of medicine at The Warren Alpert Medical School of Brown University, and Denise Luppe, oncology research nurse supervisor, told Christine that they'd just started a Phase 2 clinical trial with a less toxic combination of drugs than the standard chemo pOncology and professor of medicine at The Warren Alpert Medical School of Brown University, and Denise Luppe, oncology research nurse supervisor, told Christine that they'd just started a Phase 2 clinical trial with a less toxic combination of drugs than the standard chemo poncology research nurse supervisor, told Christine that they'd just started a Phase 2 clinical trial with a less toxic combination of drugs than the standard chemo protocol.

«The TRAIL pathway is a powerful way to suppress tumors but current approaches have limitations that we have been trying to overcome to unleash an effective and selective cancer therapy,» said Dr. Wafik El - Deiry, professor of medicine and chief of the hematology / oncology division, Penn State College of Medicine.

Small is professor of Medicine and chief of the Division of Hematology and Oncology at UCSF.

David Fajgenbaum, MD, MSc, an adjunct assistant professor of Medicine in the division of Hematology / Oncology, who is battling idiopathic multicentric Castleman disease — a rare and deadly hyperinflammatory disorder — as a patient and physician - researcher, started the Castleman Disease Collaborative Network (CDCN), with the support of immediate past Perelman dean Arthur Rubenstein.

Before joining RPCI, Dr. Koya was previously an assistant professor in the Department of Surgery, Division of Surgical Oncology, UCLA, with research focus in cancer gene therapy and immunology.

Prior to that, Dr. Hsu was Senior Medical Director at Genzyme in the Transplant and Oncology Division, where for more than nine years he was responsible for the clinical development of products in the areas of hematology, oncology, and stem cell transplant, and supported medical affairs and corporate deveOncology Division, where for more than nine years he was responsible for the clinical development of products in the areas of hematology, oncology, and stem cell transplant, and supported medical affairs and corporate deveoncology, and stem cell transplant, and supported medical affairs and corporate development.